Fig. 1 · Structure

Documents & Downloads

Cytarabine

Cat. No. A10265 CAS 147-94-4
Cytarabine inhibits DNA replication by incorporating into DNA (IC50 = 0.04 μM in L1210 and CEM cell lines).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Cytarabine incorporation into DNA was associated with loss of clonogenic survival in HL-60 cells and ex vivo AML blasts. The original study verified internucleotide incorporation and an inverse incorporation–survival relationship, supporting a DNA-directed component of cytotoxicity. [1]

AraC incorporation does not create an absolute extension block: purified human Polη extended AraC-terminated primers in two sequence contexts. These modified-DNA and AraCTP experiments describe a biochemical bypass mechanism, not inhibitory potency of parent cytarabine. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
DNA synthesis (CCRF-CEM cells) (CCRF-CEM cells) 16 nM

Cytarabine Research Summary

This section summarizes 4 in vitro studies and 2 in vivo studies of Cytarabine from 5 published references. In vitro models include HL-60 cells and ex vivo myeloblasts from one patient with AML; HCT116 and HCT116+Chr3 cells.

Cytarabine In Vitro Studies

In matched colorectal cancer models, MLH1-deficient HCT116 cells were more sensitive to cytarabine than HCT116+Chr3 cells in viability and clonogenic assays. DNA-normalized cytarabine incorporation did not differ significantly, limiting a simple greater-incorporation explanation for the response difference. [3]

DNA incorporation and clonogenic survival in human myeloid cells

Cell-based study · HL-60 cells and ex vivo myeloblasts from one patient with AML [1]

Ara-C incorporation into DNA correlated inversely with clonogenic survival. This is an association across concentration/time conditions, not proof of a unique lethal mechanism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Percentage survival versus pmol ara-C incorporated into DNAReported correlation coefficient R HL-60: R = -0.847, P < 0.0001; AML blasts: R = -0.885, P < 0.0001[1]

Literature-Reported Treatment Conditions

Treatment concentration
Clonogenic exposure: 10^-8–10^-3 M; radiolabeled incorporation series: 10^-7–10^-4 M
Exposure duration
1, 3, 6, 12 or 24 h exposure; colonies scored after 10 days (HL-60) or 7 days (patient blasts)
Method
Drug exposure followed by washing and drug-free colony assay; radiotracer incorporation quantified with nondegrading Cs2SO4 separation and DNA analysis
Reported limits
Vehicle and correlation n not specified in adopted source passage. One patient sample limits generalization.
Methods and source locations

Compound reported in the paper: Cytarabine; Compound label in the paper: ara-C

Compound-level research evidence; no Adooq lot equivalence. Reported material used as named; no salt conversion.

pp. 3235–3238, Methods and Results; Figures 1–7, especially Figure 7 and p. 3238 correlation paragraph

Percentage survival versus pmol ara-C incorporated into DNA: Correlation analysis as reported; no inferred sample size — p. 3238 Results, final paragraph; Figure 7

Polη extension of AraC-terminated DNA

Biochemical assay · Purified human Polη and 23-nt primers annealed to 39-nt G1 or G6 templates [2]

Polη extended AraC-terminated primers in both tested sequence contexts; G1 extension was qualitatively slightly lower than from the unmodified C control. No parent-drug IC50 was measured.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Extension beyond the 3′ AraC residueQualitative gel endpoint Near-full-length products in both contexts; G1 slightly less extension than unmodified C[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 nM DNA substrate; 1 nM Polη; G1: 25 μM each dATP/dGTP/dTTP; G6: 50 μM each of four nucleotides, with AraCTP replacing dCTP in the AraC arm
Exposure duration
10 min at 37 °C
Method
Radiolabeled primer extension resolved by denaturing PAGE
Vehicle
Buffered enzyme reaction; no cellular vehicle
Reported limits
Replicate n and numerical extension efficiency not reported for this gel comparison.
Methods and source locations

Compound reported in the paper: Cytarabine; Compound label in the paper: AraC

Compound-level research evidence; no Adooq lot equivalence. Modified DNA and AraCTP experiments are metabolite-level context, not parent-cytarabine potency.

Results: Biochemical Analysis; Figure 2A–B; Methods: Primer extension; Supplementary Figures 1–2

Extension beyond the 3′ AraC residue: Autoradiography; no exact efficiency inferred from bands — Figure 2A–B and Biochemical Analysis; Supplementary Figures 1–2

MLH1 status and cellular response to cytarabine

Cell-based study · MLH1-deficient HCT116 versus chromosome-3-complemented HCT116+Chr3 colorectal cancer cells [3]

HCT116 showed lower survival than HCT116+Chr3 in both short-term viability and clonogenic assays. Findings are specific to this comparator design, without clinical efficacy inference.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Surviving fraction relative to controlQualitative concentration-response Greater sensitivity in HCT116 than HCT116+Chr3 in both assays[3]

Literature-Reported Treatment Conditions

Treatment concentration
Serial dilutions; plotted concentration axes span 10^-9–10^-5 M (viability) and 10^-10–10^-6 M (clonogenic)
Exposure duration
Continuous exposure for short-term assay (day-2 treatment to day-6 readout); 24 h cytarabine exposure for clonogenic comparison
Method
CellTiter-Glo and colony formation, normalized to untreated/control wells
Vehicle
PBS for cytarabine validation; initial library screen used DMSO
Reported limits
Panel-specific replicate count is not assigned beyond caption triplicate or quadruplicate. No numerical IC50 extracted.
Methods and source locations

Compound reported in the paper: Cytarabine; Compound label in the paper: ara-C

Compound-level research evidence; no Adooq lot equivalence. Reported material used as named; no salt conversion.

Figure 1C–D; Results: Cytarabine is selective for MLH1-deficient cells; Methods: Drug screening and validation

Surviving fraction relative to control: Assays in triplicate or quadruplicate; error bars s.e.m.; no exact IC50 inferred from curves — Figure 1C–D and caption; Methods: Drug screening and validation

DNA incorporation does not explain the MLH1 response difference

Cell-based study · HCT116 and HCT116+Chr3 cells [3]

The DNA-normalized radiotracer signal did not differ significantly between the two lines. This negative result limits an explanation based on greater incorporation in MLH1-deficient cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
DNA-normalized [3H]cytarabine incorporationTwo-tailed t-test P P = 0.3845; performed in duplicate[3]

Literature-Reported Treatment Conditions

Treatment concentration
50 nM cytarabine mixed with 20 μCi [3H]cytarabine
Exposure duration
72 h
Method
DNA extraction, DNA quantification and liquid scintillation counting
Vehicle
PBS for parent cytarabine
Reported limits
Tracer molarity not supplied in the adopted method; duplicate type and error-bar semantics are not specified for Figure 4A.
Methods and source locations

Compound reported in the paper: Cytarabine; Compound label in the paper: ara-C

Compound-level research evidence; no Adooq lot equivalence. Reported material used as named; no salt conversion.

Figure 4A and caption; Methods: Analysis of cytarabine incorporation into DNA; Results: Investigation of the potential mechanism of MMR selectivity

DNA-normalized [3H]cytarabine incorporation: Figure label rounds P to 0.385; caption gives 0.3845. No exact bar height extracted. — Figure 4A caption and Results mechanism subsection

Cytarabine In Vivo Studies

In NSG mice bearing patient-derived AML xenografts, cytarabine at 60 mg/kg/day intraperitoneally for five days reduced marrow and spleen leukemia burden at day 8. Responses varied across models (4–46-fold reduction), residual disease persisted, and some individual comparisons were nonsignificant. [4]

A separate acute high-dose study found increased γ-H2AX in Purkinje-cell nuclei after cytarabine administration to wild-type mice. This damage-response finding limits assumptions of tumor-specific action; its dose, timing and model differ from the AML xenograft study. [5]

Variable cytoreduction in human AML xenografts

Animal study · NSG mice bearing patient-derived AML xenografts; 25 patient specimens in response cohort; groups described as 4–10 mice [4]

AraC reduced aggregate viable AML burden in marrow and spleen at day 8, with 4–46-fold reductions across patient-derived models. Residual leukemia remained; some individual comparisons were nonsignificant.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Viable human AML burden in bone marrow plus spleen versus vehicleFold reduction 4–46 across patient-derived models; pooled reduction labeled 9-fold in Figure 1D[4]

Conditions shared by the study groups

Route
Intraperitoneal injection
Frequency
Daily
Treatment course
5 consecutive days; endpoint day 8
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Cytarabine
60 mg/kg/day
Daily intraperitoneal PBS 1XVariable marrow/spleen AML cytoreduction with residual disease; 4–46-fold across models.[4]
Cytarabine
Model: NSG AML patient-derived xenograft mice
Reported limits: AraC formulation and injection volume not specified in adopted passage; day-8 endpoint retained without a post-final-dose interval.
Methods and source locations

Compound reported in the paper: Cytarabine; Compound label in the paper: AraC

Compound-level research evidence; no Adooq lot equivalence. Reported material used as named; no salt conversion.

First Results subsection; Figure 1A,C–D and caption; Methods: Cytarabine treatment and Assessment of leukemic engraftment

Viable human AML burden in bone marrow plus spleen versus vehicle: Flow cytometry; graphs mean ± s.e.m.; some Figure 1C individual tests marked n.s. or n.d. — Figure 1C–D; first Results subsection

Cytarabine · First Results subsection; Figure 1A,C–D and caption; Methods: Cytarabine treatment and Assessment of leukemic engraftment

Acute Purkinje-cell DNA damage response after cytarabine

Animal study · Wild-type C57BL/6J mice, approximately one month old under the default Methods regimen [5]

After high-dose acute AraC exposure, Purkinje-cell nuclear γ-H2AX profiles increased relative to PBS controls. This is a DNA damage response marker, not a behavioral ataxia endpoint or an estimate of toxicity at the AML xenograft regimen.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Purkinje-cell nuclear γ-H2AXQualitative flow-cytometry profile Increased γ-H2AX relative to PBS; no numerical fluorescence or positive-cell fraction extracted[5]

Conditions shared by the study groups

Route
Intraperitoneal injection
Frequency
One cycle (single acute administration)
Treatment course
3 h endpoint
Vehicle
PBS adjusted to pH 7.0
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Acute cytarabine
2000 mg/kg
PBS-treated micePurkinje-cell γ-H2AX profiles shifted upward relative to PBS controls.[5]
Acute cytarabine
Model: Wild-type C57BL/6J mice
Reported limits: No behavioral or long-term outcome adopted; no cross-regimen dose conversion.
Methods and source locations

Compound reported in the paper: Cytarabine; Compound label in the paper: AraC

Compound-level adverse-response context; no Adooq lot validation and no clinical dose equivalence.

Figure 4A–C; Results: Ataxia-like transcriptional profile (opening paragraph); Methods: Mice; Nuclei preparation and fluorescence-activated cell sorting

Purkinje-cell nuclear γ-H2AX: Nuclear immunostaining for NeuN, ITPR1 and γ-H2AX; main Figure 4B identifies the Purkinje gate, Figure 4C compares treatment profiles — Figure 4A–C; Results: Ataxia-like transcriptional profile (opening paragraph); Methods: Mice; Nuclei preparation and fluorescence-activated cell sorting

Acute cytarabine · Figure 4A–C; Results: Ataxia-like transcriptional profile (opening paragraph); Methods: Mice; Nuclei preparation and fluorescence-activated cell sorting

Specifications

Manufacturer Adooq Bioscience
CAS Number 147-94-4
Formula C9H13N3O5
Molecular Weight 243.2
Synonyms Cytosine b-D-arabinofuranoside; cytosine arabinoside; Ara-C
SMILES
C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 1 mg/mL (4.11 mM)
Water 41 mg/mL (168.57 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
Saline

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Cytarabine Research References

  1. [1] Major PP, Egan EM, Beardsley GP, et al. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA Proceedings of the National Academy of Sciences of the United States of America (1981). PMID: 6942429 DOI: 10.1073/pnas.78.5.3235 Source material
  2. [2] Rechkoblit O, Choudhury JR, Buku A, et al. Structural basis for polymerase η-promoted resistance to the anticancer nucleoside analog cytarabine Scientific reports (2018). PMID: 30140014 DOI: 10.1038/s41598-018-30796-w Source material
  3. [3] Hewish M, Martin SA, Elliott R, et al. Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress British journal of cancer (2013). PMID: 23361057 DOI: 10.1038/bjc.2013.3 Source material
  4. [4] Farge T, Saland E, de Toni F, et al. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism Cancer discovery (2017). PMID: 28416471 DOI: 10.1158/2159-8290.cd-16-0441 Source material
  5. [5] Liu JC, Wang D, Callen E, et al. Mechanism of cytarabine-induced neurotoxicity Nature (2025). PMID: 40562930 DOI: 10.1038/s41586-025-09210-9 Source material

Added to your cart

View Cart Checkout
Loading...